Key Highlights
- MapLight Therapeutics shares plunged about 68.78% in Monday trading to $11.41, down from a prior close of $36.56.
- The company's Phase 2 ZEPHYR trial met its primary endpoint at the 210/3 mg twice-daily dose, with a statistically significant reduction in PANSS total score versus placebo.
- A once-daily 330/6 mg dose showed numerical improvement but did not achieve statistical significance on the primary endpoint.
- The stock carries a market capitalization of approximately $9.01 million, with a 52-week range of $11.27 to $40.43.
Stock Falls Sharply Despite Company's Positive Framing
MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares collapsed in Monday trading, even as the company characterized topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in schizophrenia as positive. The sharp decline reflects a market interpretation that diverged significantly from the company's own framing of the data.
MapLight Therapeutics is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing novel therapeutics for debilitating central nervous system disorders including schizophrenia, Alzheimer's disease psychosis and autism spectrum disorder. The company's lead candidate, ML-007C-MA, is an oral M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, designed to treat psychotic symptoms while limiting peripheral side effects.
The ZEPHYR trial's 210/3 mg twice-daily dose met its primary endpoint, achieving a statistically significant reduction in PANSS total score compared to placebo at Week 5, with an effect size of 0.37 and a 4.5-point mean improvement over placebo. However, the trial's alternative 330/6 mg once-daily dose, which results in lower daily drug exposure, showed only numerical improvement over placebo and did not reach statistical significance on the primary endpoint, despite achieving separation on several secondary measures.
Market Reaction Reflects Concerns Over Dosing and Commercial Viability
Investors appear to have focused on the once-daily dose's failure to reach statistical significance as a meaningful setback, given that a once-daily regimen would likely have offered a more commercially favorable dosing profile than the twice-daily formulation that did succeed. The twice-daily dose's effect size of 0.37, while statistically significant, was also assessed by some market participants as more modest than the data investors had been positioned for heading into the readout.
MapLight shares traded within an intraday range of $11.27 to $14.50, with the stock's market capitalization falling to approximately $9.01 million. The company said it plans to engage with the FDA at an End-of-Phase 2 meeting to discuss a path forward, including a confirmatory trial intended to replicate the twice-daily results and support an eventual New Drug Application submission.
Conclusion
MapLight Therapeutics' sharp decline illustrates how a trial that meets its primary endpoint can still disappoint investors when a secondary dosing arm falls short and the winning arm's effect size comes in below expectations. Investors are likely to watch for further detail from the company's upcoming FDA meeting and the design of any confirmatory trial before reassessing the program's commercial prospects.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...